Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Fennec Pharmaceuticals (FENC) over the last 15 years, with Q3 2025 value amounting to $1.5 million.

  • Fennec Pharmaceuticals' Free Cash Flow rose 16767.91% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.0 million, marking a year-over-year decrease of 13653.79%. This contributed to the annual value of $27.0 million for FY2024, which is 25738.2% up from last year.
  • Fennec Pharmaceuticals' Free Cash Flow amounted to $1.5 million in Q3 2025, which was up 16767.91% from -$3.7 million recorded in Q2 2025.
  • Fennec Pharmaceuticals' 5-year Free Cash Flow high stood at $37.3 million for Q1 2024, and its period low was -$8.4 million during Q2 2024.
  • Moreover, its 5-year median value for Free Cash Flow was -$3.6 million (2021), whereas its average is -$1.3 million.
  • Over the last 5 years, Fennec Pharmaceuticals' Free Cash Flow had its largest YoY gain of 76894.39% in 2024, and its largest YoY loss of 11254.43% in 2024.
  • Quarter analysis of 5 years shows Fennec Pharmaceuticals' Free Cash Flow stood at -$3.0 million in 2021, then crashed by 129.95% to -$6.8 million in 2022, then grew by 28.55% to -$4.9 million in 2023, then soared by 69.67% to -$1.5 million in 2024, then skyrocketed by 201.29% to $1.5 million in 2025.
  • Its Free Cash Flow was $1.5 million in Q3 2025, compared to -$3.7 million in Q2 2025 and -$4.3 million in Q1 2025.